← Retour à la une
Océanie · Marchés régionaux · Stockhead

Racura clears hurdle for next-generation MYC-inhibiting cancer drug

Publié par Stockhead · Australie il y a 1 h
Racura clears hurdle for next-generation MYC-inhibiting cancer drug
Stockhead

Résumé détaillé

The milestone comes from a study showing the company’s new candidate RC220 delivers equivalent drug exposure to the earlier RC110 ... Read More The post Racura clears hurdle for…

Racura has cleared another key hurdle in the development of RC220. Pic: Getty Images.

Special Report: Racura Oncology has passed a key milestone in the development of its next-generation formulation of bisantrene, a cancer drug that inhibits MYC transcription.

The milestone comes from a study showing the company’s new candidate RC220 delivers equivalent drug exposure to the earlier RC110 formulation.

Racura Oncology (ASX:RAC), formerly known as Race Oncology, is developing RC220, Racura’s proprietary formulation of bisantrene, a small molecule that inhibits MYC transcription.

MYC is one of the most important drivers of cancer growth, but it has been considered undruggable despite decades of effort by the pharmaceutical industry. RC220 gets around this by acting on the MYC gene rather than the protein.

RAC has undertaken a Good Laboratory Practice (GLP) nonclinical pharmacokinetic (PK) study comparing RC220 with RC110, the earlier formulation of bisantrene used in two investigator-sponsored trials in patients with relapsed or refractory acute myeloid leukaemia (R/R AML).

Pharmacokinetics (PK) describes how the body processes a drug over time, including the concentration it reaches in the bloodstream and how long it remains before being cleared.

A PK bridging study tests whether two formulations of the same active drug produce the same drug exposure, so that clinical experience gained with one formulation can inform the development of the other.

RAC said the study found both formulations produced equivalent systemic exposure to bisantrene, supporting the use of RC110’s established clinical data and dosing levels to guide RC220’s further development.

Début de l'article, extrait de Stockhead. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Stockhead Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (stockhead.com.au)

À lire aussi